575 related articles for article (PubMed ID: 28838671)
41. Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues.
Cordes H; Bergström AL; Ohm J; Laursen H; Heegaard PM
J Immunol Methods; 2008 Sep; 337(2):106-20. PubMed ID: 18657541
[TBL] [Abstract][Full Text] [Related]
42. Prion agent diversity and species barrier.
Béringue V; Vilotte JL; Laude H
Vet Res; 2008; 39(4):47. PubMed ID: 18519020
[TBL] [Abstract][Full Text] [Related]
43. Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics.
Cali I; Castellani R; Alshekhlee A; Cohen Y; Blevins J; Yuan J; Langeveld JP; Parchi P; Safar JG; Zou WQ; Gambetti P
Brain; 2009 Oct; 132(Pt 10):2643-58. PubMed ID: 19734292
[TBL] [Abstract][Full Text] [Related]
44.
Eraña H; Fernández-Borges N; Elezgarai SR; Harrathi C; Charco JM; Chianini F; Dagleish MP; Ortega G; Millet Ó; Castilla J
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978705
[TBL] [Abstract][Full Text] [Related]
45. Effect of amphotericin B on wild-type and mutated prion proteins in cultured cells: putative mechanism of action in transmissible spongiform encephalopathies.
Mangé A; Milhavet O; McMahon HE; Casanova D; Lehmann S
J Neurochem; 2000 Feb; 74(2):754-62. PubMed ID: 10646527
[TBL] [Abstract][Full Text] [Related]
46. PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldt-Jakob Disease.
Cazzaniga FA; Bistaffa E; De Luca CMG; Portaleone SM; Catania M; Redaelli V; Tramacere I; Bufano G; Rossi M; Caroppo P; Giovagnoli AR; Tiraboschi P; Di Fede G; Eleopra R; Devigili G; Elia AE; Cilia R; Fiorini M; Bongianni M; Salzano G; Celauro L; Quarta FG; Mammana A; Legname G; Tagliavini F; Parchi P; Zanusso G; Giaccone G; Moda F
Front Aging Neurosci; 2022; 14():848991. PubMed ID: 35401151
[TBL] [Abstract][Full Text] [Related]
47. Neuropathology of Animal Prion Diseases.
Orge L; Lima C; Machado C; Tavares P; Mendonça P; Carvalho P; Silva J; Pinto ML; Bastos E; Pereira JC; Gonçalves-Anjo N; Gama A; Esteves A; Alves A; Matos AC; Seixas F; Silva F; Pires I; Figueira L; Vieira-Pinto M; Sargo R; Pires MDA
Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801117
[TBL] [Abstract][Full Text] [Related]
48. Novel strain properties distinguishing sporadic prion diseases sharing prion protein genotype and prion type.
Cracco L; Notari S; Cali I; Sy MS; Chen SG; Cohen ML; Ghetti B; Appleby BS; Zou WQ; Caughey B; Safar JG; Gambetti P
Sci Rep; 2017 Jan; 7():38280. PubMed ID: 28091514
[TBL] [Abstract][Full Text] [Related]
49. Detergents modify proteinase K resistance of PrP Sc in different transmissible spongiform encephalopathies (TSEs).
Breyer J; Wemheuer WM; Wrede A; Graham C; Benestad SL; Brenig B; Richt JA; Schulz-Schaeffer WJ
Vet Microbiol; 2012 May; 157(1-2):23-31. PubMed ID: 22226540
[TBL] [Abstract][Full Text] [Related]
50. Proteomic analysis of prion diseases: creating clarity or causing confusion?
Rubenstein R
Electrophoresis; 2012 Dec; 33(24):3631-43. PubMed ID: 23161058
[TBL] [Abstract][Full Text] [Related]
51. Amino acid sequence and prion strain specific effects on the in vitro and in vivo convertibility of ovine/murine and bovine/murine prion protein chimeras.
Kupfer L; Eiden M; Buschmann A; Groschup MH
Biochim Biophys Acta; 2007 Jun; 1772(6):704-13. PubMed ID: 17145171
[TBL] [Abstract][Full Text] [Related]
52. De novo generation of infectious prions in vitro produces a new disease phenotype.
Barria MA; Mukherjee A; Gonzalez-Romero D; Morales R; Soto C
PLoS Pathog; 2009 May; 5(5):e1000421. PubMed ID: 19436715
[TBL] [Abstract][Full Text] [Related]
53. Prion protein self-interaction in prion disease therapy approaches.
Rigter A; Priem J; Langeveld JP; Bossers A
Vet Q; 2011 Sep; 31(3):115-28. PubMed ID: 22029882
[TBL] [Abstract][Full Text] [Related]
54. Cellular prion proteins in humans and cattle but not sheep are characterized by a low-solubility phenotype.
Kuczius T; Groschup MH
Comp Immunol Microbiol Infect Dis; 2013 Dec; 36(6):599-605. PubMed ID: 23948376
[TBL] [Abstract][Full Text] [Related]
55. Host and transmissible spongiform encephalopathy agent strain control glycosylation of PrP.
Somerville RA
J Gen Virol; 1999 Jul; 80 ( Pt 7)():1865-1872. PubMed ID: 10423157
[TBL] [Abstract][Full Text] [Related]
56. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides.
Soto C; Kascsak RJ; Saborío GP; Aucouturier P; Wisniewski T; Prelli F; Kascsak R; Mendez E; Harris DA; Ironside J; Tagliavini F; Carp RI; Frangione B
Lancet; 2000 Jan; 355(9199):192-7. PubMed ID: 10675119
[TBL] [Abstract][Full Text] [Related]
57. A traceback phenomenon can reveal the origin of prion infection.
Kobayashi A; Asano M; Mohri S; Kitamoto T
Neuropathology; 2009 Oct; 29(5):619-24. PubMed ID: 19659941
[TBL] [Abstract][Full Text] [Related]
58. Creutzfeldt-Jakob disease.
Sikorska B; Knight R; Ironside JW; Liberski PP
Adv Exp Med Biol; 2012; 724():76-90. PubMed ID: 22411235
[TBL] [Abstract][Full Text] [Related]
59. Emergence of two prion subtypes in ovine PrP transgenic mice infected with human MM2-cortical Creutzfeldt-Jakob disease prions.
Chapuis J; Moudjou M; Reine F; Herzog L; Jaumain E; Chapuis C; Quadrio I; Boulliat J; Perret-Liaudet A; Dron M; Laude H; Rezaei H; Béringue V
Acta Neuropathol Commun; 2016 Feb; 4():10. PubMed ID: 26847207
[TBL] [Abstract][Full Text] [Related]
60. Minimal change prion retinopathy: Morphometric comparison of retinal and brain prion deposits in Creutzfeldt-Jakob disease.
Goodwill VS; Dryden I; Choi J; De Lillo C; Soldau K; Llibre-Guerra J; Sanchez H; Sigurdson CJ; Lin JH
Exp Eye Res; 2022 Sep; 222():109172. PubMed ID: 35803332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
